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 2016 WilThe care of patients with trisomy 13 and 18 is a source of significant controversy. While these conditions are life
limiting, indisputable data refutes the notion that these conditions are lethal or incompatible with life. Despite
such evidence, arguments of beneficence, quality of life and limited resources are invoked to make the case to
limit care to trisomy children. Lessons learned in our ignominious historywith Down syndrome should guide us as
we explore care for patients with trisomy 13 and 18. As clinicians we should strive with equipoise to carefully
examine available data, the current status of practices related to care from palliation to intensive interventions,
rise above our personal prejudices and listen to the voices of families imploring us to consider their opinions
regarding the value of the life of a child with trisomy 13 or 18. We should recall and learn from our Down
syndrome odyssey and select the road previously not taken as we chart a course to the best possible care for our
trisomy 13 and 18 sisters and brothers. © 2016 Wiley Periodicals, Inc.How to cite this article: McCaffrey MJ. 2016. Trisomy 13 and 18: Selecting the road previously not taken.
Am J Med Genet Part C Semin Med Genet 9999C:1–6.Vigorous discussions have been under-
way for several decades regarding the
level of care to be provided individuals
with trisomy 13 and 18. This dialogue
hearkens back to an era in which similar
conversations were engaged regarding
the care of infants with another chro-
mosomal disorder, Down syndrome,
later identified as trisomy 21. There
are significant differences in the severity
of some pathologies related to trisomy
13 and 18, but there have also been over
the decades significant advances in
medical and surgical care.
The reasons for the dramatic in-
crease in the survival of infants with
trisomy 21 seen over the last century
are multifactorial. Survival clearly im-
proved when generally accepted surgical
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The literature documents significant
delays in diagnosis of AV Canal, and
failure to offer repair despite acceptable
levels of pulmonary vascular resistance,
persisting into the 1990s [Sondheimer
et al., 1985; Amark and Sunnegårdh,
1999]. It was several high profile surgical
cases, including the Baby Doe case,
and controversial publications regarding
withholding of care in NICUs, that
led to political action spearheaded by
parent and disability rights groups.
These seismic societal shifts forced the
medical community to extend com-
monly accepted medical interventions
to Down syndrome patients [Mercurio,
2008].
The ongoing controversies regard-
ing care to be offered infants with
trisomy 13 and 18 in many ways mirrors
our evolution as a medical community
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regular application of surgical techni-
ques to infants with trisomy 21 in the
latter twentieth century, Down syn-
drome was characterized as life limiting,
with survivors regarded as leading a life
with little meaning and institutionaliza-
tion encouraged. In 1949, Penrose
posited a life expectancy of 8–12 years
for individuals with Down syndrome
[Penrose, 1949]. The terminology used
to refer to trisomy 21 demonstrated
general societal disregard for the value of
these lives. Scientific literature through
the 1970s demonstrates a slow progres-
sion in terminology from “defective
mongoloids” to “mongoloids” to tri-
somy 21 and Down syndrome. Life
expectancy is now as high as 55 years
[Glasson et al., 2016]. As medical
providers we have progressed from a
point in the 1970s at which 18% of
providers advocated institutionalizationfor neonatology to the Navy Surgeon General
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recognize our duty to understand and
meet the unique medical needs of Down
syndrome patients [Pueschel, 1985].The ongoing controversies
regarding care to be offered
infants with trisomy 13 and
18 in many ways mirrors our
evolution as a medical
community caring for
individuals with trisomy 21.
Until a confluence of events
led to the regular application
of surgical techniques to
infants with trisomy 21 in the
latter twentieth century,
Down syndrome was
characterized as life limiting,
with survivors regarded as
leading a life with little
meaning and
institutionalization
encouraged.The literature is replete with refer-
ences to trisomy 13 and 18 as “lethal”
conditions. So are trisomy 13 and 18
“lethal”? Wilkinson addressed this issue
and identified the two most applicable
interpretations of lethality. “Lethality”
in this context refers either to “a
condition that invariably leads to death
either in utero or in the newborn period
regardless of treatment” or “a condition
that leads to death in utero or in the
newborn period in most cases” [Wil-
kinson et al., 2014a]. The former
definition is not relevant. The latter
definition raises the question of what
percentage of death is required to classify
a condition as “lethal?” Meyer, in the
largest population-based study of sur-
vival among children with trisomy 13
or trisomy 18 published to date,demonstrates 28 days and 1 year survivals
of 25% and 12% for trisomy 13, with
36% at 28 days and 13% at one year for
trisomy 18. Meyer also notes significant
variations in survival in the nine states
included in the analysis. Survivals for
trisomy 18 at 28 days and 1 year were
55% and 22% inMassachusetts; 49% and
24% in Georgia. Not only did Meyer
demonstrate remarkable survival varia-
tion at one year, they also report that for
infants alive at one year, survival to five
years was 84% and 91% for trisomy 13
and 18 respectively [Meyer et al., 2016].
Survey data from Japan and the US,
which includes large proportions of
parents who elected to pursue medical
interventions for their children with
trisomy, report survivals of up to 50% at
1 year [Janvier et al., 2012a; Kosho et al.,
2013].
So while the ability of significant
numbers of trisomy infants to survive to
onemonth, one year and beyond is clear,
large segments of medical providers
continue to describe trisomies 13 and
18 as “lethal” and “incompatible with
life.” Wilkinson surveyed obstetricians
in Australia and New Zealand in 2013
and found that 85% believed trisomy 18
was lethal, 54% felt trisomy 18 was
incompatible with life, 78% did not
believe a child with trisomy 18 could
have a meaningful life but 77% felt that a
child born with trisomy 18 and sup-
ported would have at least a 5–20% 1-
year survival [Wilkinson et al., 2014b].
In a survey of delivery room, commu-
nity and childrens’ hospital NICU
nurses, pediatric residents and obstetric
residents, Janvier reported that 71%,
74%, 83%, 74%, and 75%, respectively
would plan to terminate a pregnancy
with a diagnosis of trisomy 18 [Janvier
et al., 2012b]. Jacobs published on the
attitudes of US neonatologists regarding
trisomy 18. The survey, while it suffers
significantly from a 13% return rate,
reports that 83% of neonatologists
believe trisomy 18 is lethal, though
only 60% feel that treatment of a child
with trisomy 18 is futile, 45% believe the
condition is incompatible with life, and
92% felt that survival of at least 5–20%
was likely at 1 year. Despite the
significant possibility of survival at1 year, only 16% felt such a life would
be meaningful [Jacobs et al., 2016].So while the ability of
significant numbers of trisomy
infants to survive to one
month, one year and beyond
is clear, large segments of
medical providers continue to
describe trisomies 13 and 18
as “lethal” and
“incompatible with life.”What is one to make of these
reports? Perhaps the best interpretation
is that many providers accept that a life,
as long as 1 year, is possible with trisomy
18, but only a minority of providers see
value in such a life. The unavoidable
conclusion is that while most providers
recognize that trisomy 13 and 18 are not
lethal, they personally equate the life of a
severely handicapped child with one of
unjustifiable suffering. In labelling tri-
somy 13 and 18 lethal, it appears that
some providers conflate their ability to
assess quality of life with lethality. For
many, death and severe handicap are
indistinguishable.
McGraw in 2008 surveyed US
neonatologists regarding whether they
would initiate delivery room resuscita-
tion in the care of a 36-week infant
“with confirmed trisomy 18 and con-
genital heart disease.” The heart disease
in this vignette was not defined. Is this a
VSD or hypoplastic left heart? It is
curious that the authors give no indica-
tion that the type of cardiac defect has
any bearing on the decisions to be made
by respondents. Nevertheless, 44% of
respondents stated that they would
initiate resuscitation, mainly at the
request of the parents. The authors
interpret this observation as the willing-
ness of 44% of neonatologists to “aban-
don the best-interest standard” and
adopt an “ethic of abdication.” In their
commentary the authors refer to
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that “the vast majority of trisomy 18
infants die within the first month” (at
odds with Rasmussen reporting 58%
mortality at onemonth for trisomy 18 in
2003 [Rasmussen et al., 2003]), that
even with intensive support trisomy 18
infants “do not flourish” and “those
who do live beyond the first year
experience shortened lives marked by
severe neurologic and physical im-
pairment.” The vignette construct and
the author commentary are symptom-
atic of a prejudice that presumes an
ability to determine that the quality of
life to be lived by trisomy 18 infants is so
dreadful that death is preferable and
parents should not even be offered
medical interventions for their child
[McGraw and Perlman, 2008].
Graham [2016] offers a more
comprehensive but similarly nihilistic
view on the care of a child with trisomy
13 or 18. While his title suggests he
intends to make the case to limit cardiac
surgery for trisomy patients with com-
plex cardiac disease, Graham’s essay is a
broader appeal to deny consideration of
all intensive care and cardiac surgery for
trisomy infants. While there have been
reports of success in cardiac surgery
offered to trisomy patients, some pa-
tients certainly will suffer significant
morbidity [Kosho et al., 2006; Kaneko
et al., 2009]. Graham is on solid ground
to advise caution in recommending
surgery for complex cardiac defects,
but he extends his recommendation to
all cardiac lesions and intensive care. He
cites three reasons: a failure to demon-
strate effectiveness for such interven-
tions, consumption of resources for “a
patient without hope for a meaningful
recovery,” and quality of life and the best
interest of the patient.
The efficacy of applying the same
neonatal intensive care practices to
trisomy infants that are offered to
seriously ill infants with a normal
karyotype has been shown to be effective.
Kosho et al. [2006] reported a 1-year
survival rate of 25% for trisomy 18 with
intensive care. Several studies of trisomy
support networks, while at risk for
reporting bias, report enhanced survival
with intensive care. Baty reported a1-year survival rate of 42% for trisomy
18 infants (25% were ventilated) and
38% for trisomy 13 patients (22% were
ventilated) [Baty et al., 1994]. Janvier
et al. [2012a] reported a survival of 53%
at 1 year for trisomy infants receiving full
intervention. It is worth noting that
Graham, in citing the Kids’ Inpatient
database report from Ma which reports
on the increased use of hospital services
by children with trisomy 13 and 18
undergoing cardiac surgery, is also
affirming that there are large numbers
of trisomy patients regularly using hospi-
tal services [Ma et al., 2013]. Nelson in a
larger evaluation of this data concluded,
“Despite the conventional understand-
ing of these syndromes (trisomy 13 and
18) as lethal, a substantial number of
children are living longer than one year
and undergoing medical and surgical
procedures as part of their treatment”
[Nelson et al., 2012].Kosho et al. reported a 1-year
survival rate of 25% for
trisomy 18 with intensive
care. Several studies of
trisomy support networks,
while at risk for reporting
bias, report enhanced survival
with intensive care.To his credit, Graham openly states
his ethical concerns with the consump-
tion of resources by patients “without
hope for a meaningful recovery.” The
question becomes one, however, of who
will define what is a meaningful recov-
ery? This is certainly a factor requiring
consideration but we must be willing to
accept our judgments in suchmatters are
steeped in our own personal prejudices.
If a decision to end a life is to be made
based on quality of life and whether
resources will be wasted on a life
“without hope for a meaningful recov-
ery”, it would seem obligatory that we
very seriously consider the input of
parents of trisomy patients. Skotko hasstudied the views of parents of individ-
uals with Down syndrome, demonstrat-
ing an overwhelming majority love and
are proud of their child with Down
syndrome. Only 4% of respondents
regretted having a child with Down
syndrome. He also found that Down
syndrome parents have a more positive
outlook on life, stronger marital bond
and their children are positively im-
pacted by their sibling [Skotko et al.,
2011].
While the possibility of severe
neurocognitive impairment in their
own child would be difficult for many
medical providers to accept, the work of
Janvier et al. [2012b] reveals that families
living with trisomy 13 and 18 are similar
to trisomy 21 families. This survey of
parents of children with trisomy 13 or
18, conducted in a social network, is
edifying. Of respondent parents, 87%
were told at some time after diagnosis
that their child was incompatible with
life, would live a life of suffering (57%),
would be a vegetable (50%), would live a
meaningless life (50%), would ruin their
marriage (23%) or would ruin their
family (23%). Of families with a full
trisomy child 40% livedmore than a year
and 21% lived at least 5 years. Of families
whose children had died, 89% reported
the overall experience of their child’s life
was positive. “Of the 159 parents whose
child lived longer than 3 months, half
stated that their child experienced more
pain than other children and half
recognized that caring for a special
needs child was more difficult than
they thought it would be. Yet, 98%
reported that this child enriched their
life. Of the families in this cohort who
had other children (n¼ 160), 82% felt
that this child had a positive effect on
siblings. When all parents were asked if
they would continue the pregnancy if
they discovered they were expecting
another child with trisomy 13 or 18,
8% responded negatively, 9% were
unsure, and 83% responded positively
or said they would not do prenatal
testing.” Based on the data we have
available from parents of children with
trisomy 13 or 18, there is little support
for the view, held by many in the
medical community, that no child with
4 AMERICAN JOURNAL OF MEDICAL GENETICS PART C (SEMINARS IN MEDICAL GENETICS) COMMENTARYtrisomy 13 or 18 should be offered the
option of intensive care based on the
presumption that they will have no
quality of life, be an insufferable burden
on their families and have no hope for
meaningful outcome.While the possibility of severe
neurocognitive impairment in
their own child would be
difficult for many medical
providers to accept, the work
of Janvier reveals that families
living with trisomy 13 and 18
are similar to trisomy 21
families. This survey of
parents of children with
trisomy 13 or 18, conducted in
a social network, is edifying.A number of single center studies
attempt to examine the comparative
effectiveness of “aggressive” or “inten-
sive” care versus non-aggressive or
palliative care in cases of trisomy 13
and 18. The common pitfalls related to
attempting to draw sound conclusions
from such studies are illustrated in
“Trisomy 18: A single-center evaluation
of management trends and experience
with aggressive obstetric or neonatal
intervention.” The authors report on 54
live births in this single center experi-
ence on the care of infants with trisomy
18 from 2004 to 2014 [Subramaniam
et al., 2016]. This publication has been
previously critiqued by Kosho and
Carey [2016] but deserves further
commentary. The authors report sur-
vival rates based on interventions they
describe as “aggressive” and “non-
aggressive.” The groups included 36
and 13 infants respectively and the
authors conclude, “Neither aggressive
obstetric nor neonatal intervention
increases survival of infants with T18
in our experience at a single center.
These results should be used incounseling families with fetuses or
newborns affected with T18.”
The first flaw in this publication
is that the authors do not have the
statistical power to reasonably make
this statement. The second difficulty is
in delineating how many infants had
“aggressive” care withdrawn after a
postnatal trisomy diagnosis was made.
It is common for “aggressive” care to be
withdrawn after a postnatal trisomy
diagnosis is made. Subramaniam reports
that 40 infants were postnatally diag-
nosed. The report does not state how
many of these infants initially had
aggressive intervention, are categorized
as such, and then had intervention
withdrawn, leading to death, and skew-
ing of comparisons. The third defi-
ciency is in meeting the requirement
that the “non-aggressive” and “aggres-
sive” groups are comparable. There is no
comparative reporting of key character-
istics in the two treatment groups, but a
comment is made regarding differences
between the two groups related to a key
element in survival, preterm birth. “It
should be noted that there was no
statistically significant difference in the
mean gestational age at birth of infants in
these two intervention groups (non-
aggressive 38.0 1.6 weeks vs. aggres-
sive 36.7 3.3 weeks; P¼ 0.06).” A
table summarizing individual patient
data is included. Review of this table
reveals a significant burden of prematu-
rity in the deaths which occurred in the
“aggressive” treatment group. There is
also an overall trend to more severe
prematurity in the “aggressive” group.
Six infants <33 weeks were ventilated,
included in the “aggressive” treatment
group, and died. This disparity in
prematurity in a report with such small
patient numbers further handicaps any
conclusions regarding comparisons of
survival in the groups designated as
“non-aggressive” and “aggressive.”
A final consideration in counseling
families regarding the prognosis and
possible treatment plans for their child
with trisomy 13 or 18 is our crude
understanding of the relationship be-
tween trisomy genotypes and pheno-
types. We classify patients with trisomy
13 and 18 as “full” or “mosaic” trisomy.Based on lymphocyte karyotype studies,
we regularly make predictions regard-
ing outcomes which rely on this
designation which disregards variability
in phenotype and perpetuates notions
of lethality. This phenotypic phenotypic
variation in those infants we describe as
“full trisomy” and “mosaics” is well
described [Slavotinek et al., 2003; Hsu
and Hou, 2007; Caba et al., 2013]. We
are just beginning to appreciate the
variable genetic expression that occurs
in infants with Down syndrome who
develop atrioventricular canal [Wang
et al., 2016]. No doubt we will identify
similar genotypic variabilities in infants
diagnosed with trisomy 13 or 18, and
in the not too distant future our use
of 5–30 cell lymphocyte analysis to
karyotypically characterize patients will
be considered primitive. More detailed
genetic characterization of trisomy
patients will ultimately allow us to
develop a more sophisticated apprecia-
tion for the natural history of the
multitude of expressions we once called
full or mosaic trisomy. This will take us
far in partnering with families as we
develop management plans. For now,
we should at least be willing to recognize
the phenotypic reality that an infant with
trisomy 13 or 18 and a diaphragmatic
hernia or hypoplastic left heart faces
much different challenges for survival
than a child without those conditions.
The intent of this commentary is
not to suggest that we can guarantee
all children with trisomy 13 or 18
an extended life, nor that we should
mandate resuscitation or all standard
medical and surgical interventions for
every trisomy infant. The intent is to
plea for truth, transparency and recog-
nition of our prejudices regarding the
decisions we make and the care we offer
patients with trisomy 13 and 18. Parents
have the right to be informed of the
unique possibilities for their child, even
if clinicians personally would not choose
to actively support a child with trisomy
13 or 18. All families will not choose to
medically intervene for their trisomy
child, but some families, perhaps many,
would welcome, with support, elements
of this challenge. Subramaniam et al.
state, “The natural history of trisomy 18
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keeping with the findings of others.”
A similar statement might have been
made by a pediatrician regarding Down
syndrome in 1960. As it was then for
Down syndrome, given medical ad-
vancements, the tremendous variation
in types of care offered trisomy 13 and
18 patients, and the commitment of
many families to care for potentially
technology dependent children with
significant mental impairment, we
must challenge Subramaniam’s conclu-
sion. Not only do we not fully under-
stand the natural history of Trisomy 13
and 18, our personal biases in predicting
quality of life have limited our interest
and willingness to explore this territory
more fully.The intent of this commentary
is not to suggest that we can
guarantee all children with
trisomy 13 or 18 an extended
life, nor that we should
mandate resuscitation or all
standard medical and surgical
interventions for every trisomy
infant. The intent is to plea
for truth, transparency and
recognition of our prejudices
regarding trisomy 13 and 18
patients.We have spent decades as medical
providers labelling trisomy 13 and 18
infants as having a “fatal fetal malforma-
tion”which is “lethal” or “incompatible
with life.” While a short life is the
fate for most children with trisomy 13
and 18, it is a life. Each trisomy child is
an individual with unique clinical
characteristics. While there are com-
monalities regarding growth and neuro-
logic outcomes for children with
trisomy 13 or 18, there is a diverse
spectrum of associated medical condi-
tions and potential life span. Labelingcare as “aggressive” and “non-aggres-
sive” with respect to all infants with
trisomy illustrates our biases. Trisomy 13
and 18 are lethal in the main only to
the point at which we limit interven-
tion and decide that it is “aggressive”.
Such limitations can be applied to
interventions that include standard
obstetrical and newborn management,
intensive care and provision of pallia-
tive care which shortens life rather than
providing comfort, basic medical needs
and the optimization of a shortened
life, via medications or starvation. In
this issue Janvier reports the discon-
certing finding that palliative care for a
prenatal diagnosis of trisomy 13 and 18
was different than that for a postnatal
diagnosis. This survey of 332 parents
in trisomy support networks revealed
that care for a prenatal diagnosis of
trisomy consisted mainly of warming
with some use of sedative medications
and no other interventions, whereas
palliative care in postnatal diagnoses
continued to include a variety of
interventions. The authors found that
the single most important factor
independently related to mortality
before discharge and at one year was
the prenatal diagnosis. Janvier et al. are
forced to conclude that the goal of
palliative care provided after a prenatal
trisomy diagnosis is as short a life as
possible. These results should give
us pause as providers to consider the
roles our prejudices play in counseling
families and treating their infants. All
infants will not benefit from interven-
tion, and many families will choose a
palliative care course, but we should
make such treatment decisions in
transparent partnership with parents
clearly stating our goals for care [Janvier
et al., 2016].
Our partnerships with families
should be predicated on the knowledge
that we are speaking about a life
changing diagnosis for a precious child
and a family. This diagnosis does not
diminish the value of the child’s life, the
child’s value to the family, nor should
we mistakenly believe we are called
upon to do so. Our duty is to as
comfortably as possible sustain life
within the mutually agreed uponparameters that exist in the spectrum
from palliation to intensive care. Our
mission must be to openly engage
families with the best available data,
talk about their child with respect and
dignity, discuss the unique medical
conditions their child possesses, review
the therapeutic options of palliative care
and standard interventions, include
specialists as required, openly recognize
the potential harm interventions may
carry, discuss long-term prognoses and
make it clear that trisomy 13 and 18 are
challenging, life limiting diagnoses gen-
erally characterized by severe cognitive
and motor delays. We should be willing
to offer support in parental decision
making which includes the opportunity
to speak with families who have cared
for a trisomy 13 or 18 child. After this
due diligence has taken place, we need
to then determine what the wishes of
the parents are and work with them
collaboratively in attempting to achieve
those goals.
As health care providers we ulti-
mately blazed new trails over a century
in the care we offer individuals with
Down syndrome. On this voyage we
gained a greater appreciation for the
intrinsic and extrinsic value of the lives
of these individuals. Decades later we
are embarking on a similar odyssey in
exploring the care we offer trisomy 13
and 18 patients. It is inaccurate to use
“fatal fetal malformations”, “lethal”
and “incompatible with life” to de-
scribe to parents their infants with
trisomy 13 and 18. As Lantos states,
“These views are no longer tenable”
[Boss et al., 2013]. History proves
that pronouncements of lethality for
these conditions will only insure one
thing. . .continued lethality. We have
much to learn about the natural history
of trisomy 13 and 18, but these will
remain uncharted waters unless we are
willing to confront our biases and
accept that many parents see an
inherent dignity and value in the life
of a child with trisomy 13 or 18 which
some of us may not. In seeking the best
approaches to the care of patients with
trisomy 13 and 18, let us select the road
previously not taken in our ignomini-
ous Down syndrome journey.
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